This Padcev market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed in the historical period can be attributed to the increasing use of combination therapies with other oncological drugs, a rising focus on treatments for rare cancers, greater emphasis on enhancing cancer treatment outcomes, the adoption of next-generation cancer therapies, and the expanding geriatric population.
Growth during the market's forecast period will be driven by the increasing demand for precision medicine, a growing emphasis on targeted cancer therapies, rising adoption of combination treatments, more investment in cancer research and development, and a shift toward more effective and less toxic therapies. Key trends during the forecast period include advancements in antibody-drug conjugate (ADC) technology, the integration of artificial intelligence in drug development, the rise of biomarker-driven targeted therapies, the use of data analytics to optimize treatment, and progress in precision oncology platforms.
The increasing incidence of bladder cancer is expected to drive the growth of the padcev market in the future. Bladder cancer involves the abnormal growth of cells in the bladder, leading to tumor formation and disruption of normal urinary function. The prevalence of bladder cancer is linked to factors such as smoking, exposure to industrial chemicals, chronic bladder infections, and a family history of the disease. Padcev helps treat bladder cancer by targeting a specific protein in cancer cells and delivering a chemotherapy drug directly to the tumor, thereby aiding in the destruction of cancer cells and improving patient outcomes in the advanced stages of the disease. For example, in March 2024, the American Cancer Society Facts and Figures, a US-based organization, projected that 83,190 new cases of urinary bladder cancer would be diagnosed in 2024, marking a slight increase from the 82,290 new cases reported in 2023. Thus, the growing incidence of bladder cancer is driving the expansion of the padcev market.
A key trend in the padcev market is the development of innovative therapies, such as combination therapy, to improve treatment efficacy and patient outcomes in cancer care. Combination therapy involves using two or more treatments or drugs together to target a specific condition, thereby enhancing the overall therapeutic effect. For instance, in August 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval from the European Commission for PADCEV (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA (pembrolizumab, a PD-1 inhibitor). This combination treatment for advanced urothelial cancer utilizes enfortumab vedotin’s targeted therapy along with KEYTRUDA’s immune checkpoint inhibition to enhance anti-cancer efficacy.
In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition enables Pfizer to significantly expand its oncology portfolio by integrating Seagen's innovative cancer treatments, including four commercial drugs, Adcetris, Padcev, Tukysa, and Tivdak. Seagen Inc., a US-based biotechnology company, specializes in developing innovative cancer therapies, including PADCEV (enfortumab vedotin).
The key company operating in the padcev market is Astellas Pharma Inc.
North America was the largest region in the padcev market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in padcev report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the padcev market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Padcev (enfortumab vedotin) is a medication used to treat certain cancer types, specifically metastatic urothelial carcinoma (a form of bladder cancer). It is an antibody-drug conjugate (ADC) that combines a targeted antibody with a chemotherapy drug. The antibody specifically binds to the Nectin-4 protein present on the surface of cancer cells. Once attached, the chemotherapy drug is released into the cancer cell, resulting in its destruction. Padcev is generally used in patients who have previously undergone treatments, including chemotherapy or immune checkpoint inhibitors.
The primary clinical indications for padcev are urothelial cancer and bladder cancer. Urothelial cancer, the most common form of bladder cancer, is effectively treated with Padcev (enfortumab vedotin-ejfv), a targeted therapy that focuses on specific proteins in cancer cells. It is distributed through various channels, including retail pharmacies and online pharmacies, and is used by different end users, such as hospitals, clinics, ambulatory care, and home care settings.
The padcev market research report is one of a series of new reports that provides padcev market statistics, including the padcev industry global market size, regional shares, competitors with the padcev market share, detailed padcev market segments, market trends, and opportunities, and any further data you may need to thrive in the padcev industry. This padcev market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The padcev market consists of sales of single-dose vials and multi-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed in the historical period can be attributed to the increasing use of combination therapies with other oncological drugs, a rising focus on treatments for rare cancers, greater emphasis on enhancing cancer treatment outcomes, the adoption of next-generation cancer therapies, and the expanding geriatric population.
Growth during the market's forecast period will be driven by the increasing demand for precision medicine, a growing emphasis on targeted cancer therapies, rising adoption of combination treatments, more investment in cancer research and development, and a shift toward more effective and less toxic therapies. Key trends during the forecast period include advancements in antibody-drug conjugate (ADC) technology, the integration of artificial intelligence in drug development, the rise of biomarker-driven targeted therapies, the use of data analytics to optimize treatment, and progress in precision oncology platforms.
The increasing incidence of bladder cancer is expected to drive the growth of the padcev market in the future. Bladder cancer involves the abnormal growth of cells in the bladder, leading to tumor formation and disruption of normal urinary function. The prevalence of bladder cancer is linked to factors such as smoking, exposure to industrial chemicals, chronic bladder infections, and a family history of the disease. Padcev helps treat bladder cancer by targeting a specific protein in cancer cells and delivering a chemotherapy drug directly to the tumor, thereby aiding in the destruction of cancer cells and improving patient outcomes in the advanced stages of the disease. For example, in March 2024, the American Cancer Society Facts and Figures, a US-based organization, projected that 83,190 new cases of urinary bladder cancer would be diagnosed in 2024, marking a slight increase from the 82,290 new cases reported in 2023. Thus, the growing incidence of bladder cancer is driving the expansion of the padcev market.
A key trend in the padcev market is the development of innovative therapies, such as combination therapy, to improve treatment efficacy and patient outcomes in cancer care. Combination therapy involves using two or more treatments or drugs together to target a specific condition, thereby enhancing the overall therapeutic effect. For instance, in August 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval from the European Commission for PADCEV (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA (pembrolizumab, a PD-1 inhibitor). This combination treatment for advanced urothelial cancer utilizes enfortumab vedotin’s targeted therapy along with KEYTRUDA’s immune checkpoint inhibition to enhance anti-cancer efficacy.
In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition enables Pfizer to significantly expand its oncology portfolio by integrating Seagen's innovative cancer treatments, including four commercial drugs, Adcetris, Padcev, Tukysa, and Tivdak. Seagen Inc., a US-based biotechnology company, specializes in developing innovative cancer therapies, including PADCEV (enfortumab vedotin).
The key company operating in the padcev market is Astellas Pharma Inc.
North America was the largest region in the padcev market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in padcev report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the padcev market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Padcev (enfortumab vedotin) is a medication used to treat certain cancer types, specifically metastatic urothelial carcinoma (a form of bladder cancer). It is an antibody-drug conjugate (ADC) that combines a targeted antibody with a chemotherapy drug. The antibody specifically binds to the Nectin-4 protein present on the surface of cancer cells. Once attached, the chemotherapy drug is released into the cancer cell, resulting in its destruction. Padcev is generally used in patients who have previously undergone treatments, including chemotherapy or immune checkpoint inhibitors.
The primary clinical indications for padcev are urothelial cancer and bladder cancer. Urothelial cancer, the most common form of bladder cancer, is effectively treated with Padcev (enfortumab vedotin-ejfv), a targeted therapy that focuses on specific proteins in cancer cells. It is distributed through various channels, including retail pharmacies and online pharmacies, and is used by different end users, such as hospitals, clinics, ambulatory care, and home care settings.
The padcev market research report is one of a series of new reports that provides padcev market statistics, including the padcev industry global market size, regional shares, competitors with the padcev market share, detailed padcev market segments, market trends, and opportunities, and any further data you may need to thrive in the padcev industry. This padcev market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The padcev market consists of sales of single-dose vials and multi-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Padcev Market Characteristics4. Padcev Market Trends and Strategies5. Padcev Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Padcev Pricing Analysis & Forecasts30. Global Padcev Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Padcev Market32. Recent Developments in the Padcev Market
3. Padcev Market Biologic Drug Characteristics
6. Global Padcev Growth Analysis and Strategic Analysis Framework
8. Padcev Market Segmentation
9. Global Padcev Epidemiology of Clinical Indications
10. Padcev Market Regional and Country Analysis
11. Asia-Pacific Padcev Market
12. China Padcev Market
13. India Padcev Market
14. Japan Padcev Market
15. Australia Padcev Market
16. South Korea Padcev Market
17. Western Europe Padcev Market
18. UK Padcev Market
19. Germany Padcev Market
20. France Padcev Market
21. Eastern Europe Padcev Market
22. North America Padcev Market
23. USA Padcev Market
24. Canada Padcev Market
25. South America Padcev Market
26. Middle East Padcev Market
27. Africa Padcev Market
28. Padcev Market Competitive Landscape and Company Profiles
29. Global Padcev Market Pipeline Analysis
33. Padcev Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Padcev Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on padcev market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for padcev? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The padcev market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Clinical Indication: Urothelial Cancer; Bladder Cancer2) by Distribution Channel: Retail Pharmacies; Online Pharmacies
3) by End-User: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Mentioned:Astellas Pharma Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Astellas Pharma Inc.
